Tirzepatide
Dual GLP-1 and GIP receptor agonist for powerful weight management and glycemic control
Overview
Tirzepatide is a once-weekly injectable medication that activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors — making it a dual agonist with superior weight loss results compared to GLP-1 alone. It improves blood sugar control, reduces appetite, and promotes significant fat loss. Compounded with Pyridoxine (B6) to help reduce nausea.
- Weight management and obesity treatment
- Type 2 diabetes glycemic control
- Appetite regulation and reduced food cravings
- Cardiovascular risk reduction
- Lowering A1C and BMI
Dosage & Instructions
Form
Subcutaneous injection
Amount
As prescribed — titrated from starting dose
Frequency
Once weekly
Timing
Same day each week, any time of day
Inject subcutaneously into the abdomen, thigh, or upper arm. Rotate injection sites weekly. Follow your provider's titration schedule carefully.
Dosage Schedule
| When | Dose | Notes |
|---|---|---|
| Weeks 1–4 | Starting dose as prescribed | Low starting dose to minimize GI side effects |
| Weeks 5–8 | Increased dose per provider plan | Titrate up as tolerated |
| Maintenance | Target maintenance dose | Continue weekly as directed |
Side Effects
Common
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Decreased appetite
Less Common
- Fatigue
- Dizziness
- Abdominal discomfort
- Injection site reactions
Serious — Seek Care
- Pancreatitis — stop and contact provider if severe abdominal pain occurs
- Gallbladder problems
- Hypoglycemia when combined with other diabetes medications
- Increased heart rate
Drug Interactions
- Insulin and diabetes medications — increased hypoglycemia risk
- Oral medications — delayed gastric emptying may affect absorption
- Inform your provider of all current medications